Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35 (last close)
Last close data
🏠 Home   ➤    Stock news

Among the sharpest declines in the SBF 120, Medincell stock falls 3.5%

The Montpellier-based biopharmaceutical company is catching its breath after several sessions of rebound, in a Paris market oriented downward. The decline occurs as two brokerage firms raised their targets this week.


Among the sharpest declines in the SBF 120, Medincell stock falls 3.5%

A decline of 3.65% that places the stock among the weakest performers in the SBF 120

Medincell stock declines by 3.65% to €25.32, while the SBF 120 loses 0.81%. The security ranks among the index's largest declines and thus drops back below the resistance level of €26.76 breached the previous day. This movement does not call into question the recent momentum: the stock still gains 5.06% over the week and remains above its three moving averages, with the 20-day moving average at €23.01 being 10% below the current price.

The RSI at 65 indicates a still bullish configuration, without an overbought zone. Over three months, however, performance remains negative at -13.58%, which leaves the weekly gain well below the quarterly decline.

Two price target increases in two days, Stifel and Portzamparc

Stifel raised its target from €33 to €36.50 on October 6, followed by Portzamparc which raised its target yesterday from €30 to €31.40 with a buy rating. According to analyst opinions, these targets stand respectively 24% and 44% above the current price. On valuation, the consensus of tracked analysts points to a P/E ratio of 506.4 times earnings for the current fiscal year, reduced to 60.3 times those of the following fiscal year. The stock trades at €25.32, just above its 200-day moving average (€24.79), which remains the benchmark to monitor following this decline.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: T4 2025

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours